Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSTEM Inj. in Moderate to Severe Atopic Dermatitis (Phase II, Korea)
KCT0004772Phase 2Active, not recruiting
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Dec 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ADSTEM in atopic dermatitis (AD) (2 arms), sponsored by EHL Bio Co., Ltd. Started Dec 2019; status: active, not recruiting.
02
Drugs
ADSTEM
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on KCT0004772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004772.